drugset / Trial / NCT05232266
The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a double blind, randomised, placebo-controlled clinical trial aiming to assess the effectiveness of Caralluma fimbriata on stress, sleep and neurotransmitters in a healthy adult population.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2023-05-19
- Completion
- 2023-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caralluma Fimbriata | Unknown | 500 mg | — |
Indications
No indication recorded.